バイオテクノロジーと製薬サービスのアウトソーシング市場規模、シェア、成長分析、サービス別、最終用途別、地域別 - 産業予測、2025～2032年

世界のバイオテクノロジーと製薬サービスのアウトソーシング市場規模は2023年に452億米ドルと評価され、予測期間（2025-2032年）のCAGRは5.7%で、2024年の477億8,000万米ドルから2032年には744億4,000万米ドルに成長する見通しです。

バイオテクノロジーと製薬サービスのアウトソーシング市場は、世界のヘルスケア・エコシステムにとって不可欠なものとなっており、より迅速な医薬品開発と研究能力の強化を推進しています。この分野では、製薬企業やバイオテクノロジー企業が創薬、開発、製造を専門の第三者プロバイダーに委託することで、業務効率を向上させながら中核機能に集中することができます。研究開発コストの上昇や専門的な知識に対する需要に影響され、この市場は大きな成長を遂げています。アウトソーシングの主な分野には、研究開発、臨床試験、製造が含まれ、CRO（医薬品開発業務受託機関）やCMO（医薬品製造業務受託機関）が重要な役割を果たしています。アウトソーシングは財務リスクを軽減し、スケジュールを早めるだけでなく、市場の需要に柔軟に対応することができます。COVID-19の大流行は、ワクチン開発の迅速化におけるアウトソーシングの重要性を浮き彫りにしたが、一方でAIと個別化医療の革新は、この進化する業界におけるアウトソーシングの未来を形作り続けています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーター分析と影響
  • 競争企業間の敵対関係
  • 代替品の脅威
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 供給企業の交渉力

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩
• 規制情勢
• ケーススタディ

バイオテクノロジーと製薬サービスのアウトソーシング市場規模：サービス別

• 市場概要
• コンサルティング
• 規制関連業務
• 製品設計と開発
• 監査と評価
• 製品メンテナンス
• トレーニングと教育
• その他

バイオテクノロジーと製薬サービスのアウトソーシング市場規模：最終用途別

• 市場概要
• 製薬会社
• バイオテクノロジー企業

バイオテクノロジーと製薬サービスのアウトソーシング市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• The Quantic Group（US）
• IQVIA（US）
• Lachman Consultant Services, Inc.（US）
• GMP Pharmaceuticals Pty Ltd.（Australia）
• Concept Heidelberg GmbH（Germany）
• Charles River Laboratories（US）
• ICON plc（Ireland）
• Samsung Biologics（South Korea）
• Lonza（Switzerland）
• Syneos Health（US）

結論と推奨事項

Global Biotechnology & Pharmaceutical Services Outsourcing Market size was valued at USD 45.2 billion in 2023 and is poised to grow from USD 47.78 billion in 2024 to USD 74.44 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The biotechnology and pharmaceutical services outsourcing market has become integral to the global healthcare ecosystem, driving faster drug development and enhanced research capabilities. This sector enables pharmaceutical and biotech firms to delegate drug discovery, development, and manufacturing to specialized third-party providers, allowing them to concentrate on their core functions while improving operational efficiency. Influenced by rising R&D costs and the demand for specialized expertise, this market has experienced significant growth. Key areas of outsourcing include research and development, clinical trials, and manufacturing, with contract research organizations (CROs) and contract manufacturing organizations (CMOs) playing crucial roles. Outsourcing not only mitigates financial risks and accelerates timelines but also provides flexibility in responding to market demands. The COVID-19 pandemic highlighted its importance in expediting vaccine development, while innovations in AI and personalized medicine continue to shape the future of outsourcing in this evolving industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biotechnology & Pharmaceutical Services Outsourcing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biotechnology & Pharmaceutical Services Outsourcing Market Segmental Analysis

Global Biotechnology & Pharmaceutical Services Outsourcing Market is segmented by Service, End-use, and region. Based on Service, the market is segmented into Consulting, Regulatory Affairs, Product Design & Development, Auditing and Assessment, Product Maintenance, Training & Education, and Others. Based on End-use, the market is segmented into Pharmaceutical Companies, and Biotech Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biotechnology & Pharmaceutical Services Outsourcing Market

The Global Biotechnology and Pharmaceutical Services Outsourcing market is significantly driven by the need for cost efficiency and flexibility among pharmaceutical and biotechnology companies. By outsourcing various phases of drug development and manufacturing to specialized contract research organizations (CROs) and contract manufacturing organizations (CMOs), these companies can achieve substantial cost savings. This approach enables them to leverage expert knowledge and advanced infrastructure without the burdensome financial commitment of building and maintaining their own facilities. Furthermore, the outsourcing model offers the adaptability to adjust operational capacity according to project demands, facilitating a more responsive and efficient development process.

Restraints in the Global Biotechnology & Pharmaceutical Services Outsourcing Market

The Global Biotechnology and Pharmaceutical Services Outsourcing market faces several significant restraints, particularly concerning quality control and intellectual property issues. When outsourcing vital components of drug development and manufacturing, companies often grapple with the challenge of upholding stringent quality control standards while ensuring the protection of their proprietary information. There is a heightened need for careful management to guarantee that outsourced services comply with regulatory requirements and effectively safeguard sensitive data. Failure to address these concerns could jeopardize product quality and lead to potential risks regarding intellectual property theft, ultimately impacting a company's reputation and competitiveness in the market.

Market Trends of the Global Biotechnology & Pharmaceutical Services Outsourcing Market

The Global Biotechnology & Pharmaceutical Services Outsourcing market is experiencing a notable trend characterized by the rising demand for specialized services. As biotechnology and pharmaceutical companies pivot towards outsourcing, they are increasingly partnering with contract research organizations (CROs) and contract manufacturing organizations (CMOs) that offer targeted expertise in critical areas such as clinical trials, drug development, regulatory compliance, and manufacturing processes. This shift is largely motivated by the desire to leverage specialized knowledge without the financial and operational burden of maintaining extensive in-house resources, thereby enhancing efficiency and driving innovation throughout the drug discovery and commercialization landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Biotechnology & Pharmaceutical Services Outsourcing Market Size by Service & CAGR (2025-2032)

• Market Overview
• Consulting
• Regulatory Affairs
• Product Design & Development
• Auditing and Assessment
• Product Maintenance
• Training & Education
• Others

Global Biotechnology & Pharmaceutical Services Outsourcing Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Pharmaceutical Companies
• Biotech Companies

Global Biotechnology & Pharmaceutical Services Outsourcing Market Size & CAGR (2025-2032)

• North America, (Service, End-use)
  • US
  • Canada
• Europe, (Service, End-use)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Service, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Service, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Service, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• The Quantic Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lachman Consultant Services, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GMP Pharmaceuticals Pty Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Concept Heidelberg GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation